Skin pain and sleep quality numeric rating scales for children aged 6 months to 5 years with atopic dermatitis

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	A. S. Paller, E. C. Siegfried, S. E. Marron, M. Clark, N. Harris, K. Kosa, S. Qin, D. Whalley, J. Chao, A. Bansal, C. C. Chuang, Z. Wang
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Journal of the European Academy of Dermatology and Venereology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Dupilumab treatment in children aged 6 months to 5 years with severe atopic dermatitis
di: Audrey Lasek, et al.
Pubblicazione: (2025)

The Eczema Area and Severity Index: An update of progress and challenges in its measurement of atopic dermatitis after 20 years of use
di: M. E. Jacobson, et al.
Pubblicazione: (2024)

Association of atopic dermatitis with depression and sleep quality in an Asian general population cohort of 8887 participants
di: Yik Weng Yew, et al.
Pubblicazione: (2024)

Harmonizing body surface area assessments between the Eczema Area and Severity Index, SCORing Atopic Dermatitis, and handprint methods utilizing one shared measurement—A proposal to improve efficiency and reduce error in atopic dermatitis trials
di: M. E. Jacobson, et al.
Pubblicazione: (2024)

Understanding socioeconomic outcomes in Danish children with moderate‐to‐severe atopic dermatitis
di: Ilona Tadulewicz, et al.
Pubblicazione: (2025)

Long‐term efficacy of abrocitinib in patients with moderate‐to‐severe atopic dermatitis to 2 years
di: Melinda J. Gooderham, et al.
Pubblicazione: (2026)

Increasing dosing intervals for biologics in atopic dermatitis‐why, who, when and how?
di: M. E. Jacobson, et al.
Pubblicazione: (2025)

Translating 6‐year trial safety data of upadacitinib in atopic dermatitis into clinical practice
di: Lian F. van der Gang, et al.
Pubblicazione: (2026)

Long‐term socioeconomic outcomes in Danish children with moderate‐to‐severe atopic dermatitis
di: Sigrun Alba Johannesdottir Schmidt, et al.
Pubblicazione: (2025)

The long road to atopic disease modification in infants with atopic dermatitis
di: Thomas Hultsch
Pubblicazione: (2024)

Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years
di: Christopher G. Bunick, et al.
Pubblicazione: (2025)

French guidelines for the management of atopic dermatitis
di: Nina Sigg, et al.
Pubblicazione: (2025)

Beyond events per 100 patient‐years: Interpreting 6‐year upadacitinib safety in atopic dermatitis
di: Anxin Wen
Pubblicazione: (2025)

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study
di: Matthias Augustin, et al.
Pubblicazione: (2025)

Methotrexate for atopic dermatitis: The right dosing and best‐performance administration route
di: A. Nosbaum, et al.
Pubblicazione: (2025)

Phototherapy for atopic dermatitis: Is the light still shining?
di: Adrian Tanew
Pubblicazione: (2024)

Drug utilization among young adults with atopic dermatitis: Influence of sex, socio‐economic status and disease severity
di: P. L. Carmanius, et al.
Pubblicazione: (2024)

Efficacy and safety of tozorakimab in moderate‐to‐severe atopic dermatitis: A Phase 2a randomized controlled trial (FRONTIER‐2)
di: J. I. Silverberg, et al.
Pubblicazione: (2024)

Five‐year drug survival of dupilumab in atopic dermatitis: Italian landscape AD real‐world study
di: Luigi Gargiulo, et al.
Pubblicazione: (2025)

Infant palmar hyperlinearity and type 2 inflammatory markers predict atopic dermatitis at 1 year of age
di: Iben Frier Ruge, et al.
Pubblicazione: (2025)

Psychological impact on flare patterns and severity of atopic dermatitis
di: Mia‐Louise Nielsen, et al.
Pubblicazione: (2024)

An alternative interpretation of the diagnosis of atopic dermatitis in the Boy with an Orange
di: Nicolas Kluger
Pubblicazione: (2026)

Infectious risk with JAKi : What about atopic dermatitis?
di: Lea Hoisnard, et al.
Pubblicazione: (2025)

Langerhans cells: Central players in the pathophysiology of atopic dermatitis
di: Yi Pan, et al.
Pubblicazione: (2024)

International consensus on methotrexate dosing for patients with atopic dermatitis: An eDelphi study
di: Anouk G. M. Caron, et al.
Pubblicazione: (2024)

T helper and IL ‐20 cytokine signatures distinguish atopic dermatitis from contact dermatitis subtypes
di: Axel De Greef, et al.
Pubblicazione: (2025)

Clearance of Darier disease lesions in a patient with concomitant atopic dermatitis treated with abrocitinib
di: M. Bianco, et al.
Pubblicazione: (2024)

Efficacy and tolerance of dupilumab in patients with moderate‐to‐severe atopic dermatitis and obesity
di: Joséphine Dupuis, et al.
Pubblicazione: (2024)

Addressing existing gaps in the management of young adults with atopic dermatitis
di: Magdalena Trzeciak, et al.
Pubblicazione: (2024)

Bridging the gap: Treatment of atopic dermatitis with dupilumab during pregnancy
di: Christian Vestergaard, et al.
Pubblicazione: (2025)

Tattoos in patients with atopic dermatitis: What the dermatologist should know?
di: Nicolas Kluger
Pubblicazione: (2025)

Leveraging artificial intelligence to pursue treatment personalization in atopic dermatitis
di: Bruno Duarte
Pubblicazione: (2024)

Treatment‐associated phenotype switching between psoriasis and atopic dermatitis
di: Tiago Torres, et al.
Pubblicazione: (2026)

Impact of prior biologic exposure on drug survival in atopic dermatitis
di: Xu Li, et al.
Pubblicazione: (2025)

Improvement and maintenance of clinical outcome assessments in atopic dermatitis with amlitelimab
di: Andrew Blauvelt, et al.
Pubblicazione: (2025)

Correspondence to ‘Cardiovascular and thromboembolic risks of JAK inhibitors in atopic dermatitis’
di: Shiuan‐Chih Chen, et al.
Pubblicazione: (2025)

Dissecting the roles of oxidative stress gene expression in atopic dermatitis
di: Zhi‐Qing Zhan, et al.
Pubblicazione: (2024)

Interpreting the risk of venous thromboembolism with JAK inhibitors in atopic dermatitis
di: Sheng Li, et al.
Pubblicazione: (2025)

Upadacitinib improves symptoms of concomitant allergic rhinitis or allergic asthma in patients with severe atopic dermatitis: A 16‐week multicentre retrospective study
di: L. Gargiulo, et al.
Pubblicazione: (2024)

Efficacy of abrocitinib and dupilumab in itch‐dominant atopic dermatitis: An analysis of 2 trials
di: Jonathan I. Silverberg, et al.
Pubblicazione: (2026)